Optical Biopsy to Improve the Diagnosis of Kidney Cancer

Trial Title: Optical Biopsy to Improve the Diagnosis of Kidney Cancer

NCT ID: NCT02073110

Condition: Kidney Cancer

Conditions: Official terms:
Kidney Neoplasms
Carcinoma, Renal Cell

Conditions: Keywords:
Kidney cancer
Renal mass
Small renal mass
Optical Coherence Tomography
OCT
Diffuse Reflectance Spectroscopy
DRS
Optical Biopsy
OB

Study type: Observational

Overall status: Unknown status

Study design:

Time perspective: Prospective

Intervention:

Intervention type: Device
Intervention name: Percutaneous Optical Biopsy (OCT and DRS)
Arm group label: ≥ 18 years, solid enhancing renal mass suspected for RCC

Summary: Data from the American Cancer Society shows a 70% increase in incidence of kidney and renal pelvis cancer between 2000 and 2010. This increase is attributed to small renal masses (SRM) that are incidentally discovered by abdominal radiological imaging. However, 30% of resected SRMs appear benign on histological examination. Conventional biopsy is currently used to provide pathological information prior to resection. However, its non-diagnostic value is high, up to 33% in SRMs, showing the need for diagnostic improvement. The investigators have shown that optical biopsy (OB) can differentiate malignant from benign tissue and tumor subtypes. However, translation to the clinic requires a phase 2 clinical study. The investigators will use an OB probe that can be combined with a needle puncture during classical biopsy procedures, additionally providing real time micro-scale images containing quantitative information about tissue properties. The investigators are convinced that OB will greatly improve the diagnosis of renal tumor pathology.

Detailed description: Rationale: Renal biopsies can be used in patients with renal mass lesions to diagnose whether it concerns a malignant or benign mass. In case of malignancy, surgery will be the following step. However, 7 to 33% of biopsies are non-diagnostic, what can result in unnecessary surgery (even up to 30% in small renal masses). The investigators think that optical biopsy (OB), a new diagnostic tool based on the absorption en reflection of light in tissues, reduces the non-diagnostic biopsy rate. This could have a direct impact on the quality of life of the patients that are therefore scheduled for an unnecessary surgical procedure. Also, concerns about overtreatment have led to the concept of focal therapy, a selective patient tailored nephron sparing surgical or ablation technique of a lesion, reducing lifetime morbidity and side effects without compromising life expectancy. For this novel form of treatment, accurate identification, grading and demarcation of a lesion is crucial and OB is the ideal platform to provide this approach to an improved cure. Objectives: Primary - The accuracy of DRS and OCT in the diagnostic of renal malignancy Secondary - The accuracy of DRS and OCT in the diagnostic of renal malignancy and in distinguishing among the 3 main RCC subtypes - The accuracy of the combination of the DRS and OCT Study design: This is a prospective, observational, multi-centre in-vivo study. Study population: Patients ≥ 18 years of age, with a solid enhancing renal mass suspected for renal cell carcinoma (RCC) and candidates for active (surgical) treatment of the renal mass. Intervention: Patients will receive an ultrasound guided percutaneous OB followed by a Core biopsy (CB) during the same procedure. The planned institutional surgical protocol will be followed irrespective of the results of OB and CB. During surgery (radical/partial, open/laparoscopic, percutaneous ablation) a new set of DRS and OCT measurements of the tumor and normal tissue will be performed. Main study parameters/endpoints: 1. To determine the accuracy of OB to differentiate renal tumor pathology from benign tissue by means of minimal invasive quantitative DRS and OCT. 2. To determine the differentiation capability of OCT this combined technique to distinguish between the three most common RCC sub-types. 3. To determine whether OB is a good alternative to the percutaneous biopsy for diagnosing renal cancer.

Criteria for eligibility:

Study pop:
Patients ≥ 18 years of age, with a solid enhancing renal mass suspected for renal cell carcinoma (RCC) and candidates for active (surgical) treatment of the renal mass.

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - Age ≥ 18 years - Solid, enhancing mass on cross sectional imaging suspect for RCC - Scheduled for total or partial nephrectomy or for laparoscopic cryoablation. - Signed informed consent Exclusion Criteria: - Patients with a renal mass that are not candidates for active treatment will be excluded from the study

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Free University Medical Center

Address:
City: Amsterdam
Zip: 1081 HV
Country: Netherlands

Status: Not yet recruiting

Contact:
Last name: RJA van Moorselaar, MD. PhD.

Phone: +31204440272
Email: Rja.vanmoorselaar@vumc.nl

Facility:
Name: Academic Medical Center

Address:
City: Amsterdam
Zip: 1105 AZ
Country: Netherlands

Status: Recruiting

Contact:
Last name: MP Laguna Pes, MD. PhD.

Phone: +31205666928
Email: m.p.lagunapes@amc.uva.nl

Contact backup:
Last name: Peter Wagstaff, MD.

Phone: +31205666493
Email: p.g.wagstaff@amc.uva.nl

Investigator:
Last name: Peter Wagstaff, MD
Email: Sub-Investigator

Start date: August 2013

Lead sponsor:
Agency: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Agency class: Other

Source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT02073110